Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus

NCT00085969 · Completed

Last updated 2026-05-28

This clinical trial tested whether the medication exenatide, taken alone, could help lower blood sugar levels in adults with type 2 diabetes over a 28-day period.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 99 people

Who can join Ages 18–75 · all sexes

Timeline Started 2003-09 · est. completion 2004-01

Where 23 sites · United States

What this study is testing ClinicalTrials.gov NCT00085969 ↗

Description as written by the study sponsor.

The purpose of this study is to evaluate the safety and efficacy of a 28-day regimen of exenatide (AC2993), given as a monotherapy to subjects with type 2 diabetes mellitus.

Treatments tested

Placebo 0.04 mL twice daily Drug

Subcutaneously injected, 0.04 mL, twice daily
Placebo 0.04 mL once daily Drug

Subcutaneously injected, 0.04 mL, once daily
Placebo 0.08 mL once daily Drug

Subcutaneously injected, 0.08 mL, once daily
B - Exenatide 10 mcg twice daily also known as ACC2993, synthetic exendin-4 Drug

Subcutaneously injected, 10 mcg (0.04 mL), twice daily
C - Exenatide 10 mcg once daily also known as ACC2993, synthetic exendin-4 Drug

Subcutaneously injected, 10 mcg (0.04 mL), once daily
Exenatide 20 mcg once daily also known as ACC2993, synthetic exendin-4 Drug

Subcutaneously injected, 20 mcg (0.08 mL), once daily

Main thing measured	Change in HbA1c (glycosylated hemoglobin) from Baseline to Day 28
Sponsor	AstraZeneca
Conditions studied	Diabetes Mellitus, Type 2
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00085969 ↗